Key Points
- MediWound COO Shmuel Hess sold 3,958 shares at an average price of $12.92, generating $51,137.36; he also sold 1,865 shares for $24,245 the previous day.
- MediWound shares opened at $12.66, down 4.4%, near their 12-month low of $12.52. The company reported a quarterly loss of $0.77 per share, slightly worse than analyst expectations, despite revenue exceeding forecasts.
- Analyst sentiment is mixed, with an overall “Hold” rating and an average price target of $33.00; institutional investors own approximately 46.83% of the company.
MediWound Ltd. (NASDAQ:MDWD - Get Free Report) COO Shmuel Hess sold 1,865 shares of the business's stock in a transaction dated Wednesday, August 26th. The shares were sold at an average price of $13.00, for a total transaction of $24,245.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.
Shmuel Hess also recently made the following trade(s):
- On Thursday, August 27th, Shmuel Hess sold 3,958 shares of MediWound stock. The shares were sold at an average price of $12.92, for a total transaction of $51,137.36.
MediWound Stock Performance
Shares of NASDAQ MDWD opened at $12.66 on Friday. The firm has a market cap of $162.68 million, a P/E ratio of -7.03 and a beta of 0.15. MediWound Ltd. has a 1 year low of $12.52 and a 1 year high of $20.30. The firm's 50 day moving average price is $14.16 and its 200 day moving average price is $15.64.
MediWound (NASDAQ:MDWD - Get Free Report) last issued its quarterly earnings results on Thursday, August 13th. The biopharmaceutical company reported ($0.77) earnings per share for the quarter, missing the consensus estimate of ($0.76) by ($0.01). MediWound had a negative net margin of 170.10% and a negative return on equity of 47.24%. The business had revenue of $3.09 million during the quarter, compared to analyst estimates of $2.59 million. As a group, equities analysts predict that MediWound Ltd. will post -2.31 EPS for the current year.
Analyst Upgrades and Downgrades
Several research firms recently commented on MDWD. Wall Street Zen lowered MediWound from a "sell" rating to a "strong sell" rating in a research note on Saturday, August 15th. Weiss Ratings restated a "sell (d-)" rating on shares of MediWound in a report on Friday, July 17th. Oppenheimer restated an "outperform" rating and issued a $30.00 price target (down from $32.00) on shares of MediWound in a report on Friday, August 14th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $36.00 price objective on shares of MediWound in a research note on Thursday, May 28th. Two research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus price target of $33.00.
Check Out Our Latest Analysis on MDWD
Hedge Funds Weigh In On MediWound
Hedge funds and other institutional investors have recently modified their holdings of the company. Kotler Kevin acquired a new position in shares of MediWound in the 4th quarter valued at about $6,225,000. Sphera Funds Management LTD. increased its position in MediWound by 24.3% during the 4th quarter. Sphera Funds Management LTD. now owns 230,347 shares of the biopharmaceutical company's stock worth $4,252,000 after purchasing an additional 45,077 shares in the last quarter. Silverberg Bernstein Capital Management LLC raised its holdings in MediWound by 8.7% in the first quarter. Silverberg Bernstein Capital Management LLC now owns 200,005 shares of the biopharmaceutical company's stock valued at $3,222,000 after buying an additional 16,081 shares during the period. Millennium Management LLC raised its holdings in MediWound by 355.6% in the third quarter. Millennium Management LLC now owns 175,383 shares of the biopharmaceutical company's stock valued at $3,160,000 after buying an additional 136,884 shares during the period. Finally, UBS Group AG raised its holdings in MediWound by 90.1% in the fourth quarter. UBS Group AG now owns 145,057 shares of the biopharmaceutical company's stock valued at $2,678,000 after buying an additional 68,756 shares during the period. 46.83% of the stock is owned by institutional investors and hedge funds.
MediWound Company Profile
(
Get Free Report)
MediWound Ltd. (NASDAQ: MDWD) is a biopharmaceutical company headquartered in Yavne, Israel, specializing in the development and commercialization of innovative enzymatic therapies for burn and wound management. Since its establishment, the company has focused on advancing proteolytic enzyme technology to address critical needs in debridement and tissue repair. MediWound operates research and development facilities in Israel and maintains commercial offices in the United States to support its global market presence.
The company's lead product, NexoBrid®, is an enzyme-based debriding agent designed to selectively remove burn eschar without harming viable tissue.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
